All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Expansion of Luspatercept Indication Underscores Evolving Treatment Landscape for Low-Risk MDS

April 30th 2024

Benjamin Tomlinson, MD, discusses the first-line approval of luspatercept and other ongoing research in low-risk MDS.

Examining Potential Markers of Osteosarcoma Stem Cells Is at the Forefront of Research

April 30th 2024

R. Lor Randall, MD, FACS, discusses research examining ALDH1A1 and CD44, potential markers of osteosarcoma stem cells, and how further research may be warranted with cancer stem cells.

Studying Endometrial Cancer in Black Women

April 30th 2024

Two new grants from the U.S. Department of Defense will support Sylvester Comprehensive Cancer Center studies of endometrial cancer in Black women.

NK Cell Therapy IGNK001 Receives FDA Orphan Drug Designation for AML

April 30th 2024

The investigational therapy IGNK001 has received orphan drug designation from the FDA for patients with acute myeloid leukemia.

Chidamide Plus R-CHOP Approved in China for MYC/BCL2–Expressing DLBCL

April 30th 2024

Chidamide plus R-CHOP has received approval from China’s NMPA for the management of diffuse large B-cell lymphoma.

The Road Beyond Frontline CDK4/6 Inhibitors in HR+/HER2– Metastatic Breast Cancer Examines Combinations

April 30th 2024

Erin Frances Cobain, MD, highlights the current role of endocrine therapy and CDK4/6 inhibitors in HR-positive, HER2-negative metastatic breast cancer.

Tumor Intrinsic Subtype Affects Relationship Between pCR and EFS in ERBB2+/HER2+ Early Breast Cancer

April 30th 2024

Tumor intrinsic subtype impacted the association between pCR and EFS after chemotherapy and ERBB2/HER2 blockade in ERBB2/HER2-positive early breast cancer.

PROs Underscore Utility of Mirvetuximab Soravtansine in FRα+ Ovarian Cancer

April 29th 2024

Gottfried E. Konecny, MD, discusses PRO data for mirvetuximab soravtansine derived from the phase 3 MIRASOL trial.

FDA Approves Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer

April 29th 2024

The FDA granted full approval to tisotumab vedotin for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

Early Responses With CTX130 Renew Hope for Anti-CD70 CAR T-Cell Therapy in Advanced RCC

April 29th 2024

Samer A. Srour, MB ChB, MS, explains the significance of early safety and efficacy data with CTX130 in CD70-expressing clear cell renal cell carcinoma.

ASCO Updates Advanced HCC Treatment Guideline

April 29th 2024

ASCO has announced a guideline update for systemic therapy in advanced hepatocellular carcinoma.

Trastuzumab Deruxtecan Improves PFS in Metastatic HR+/HER2-Low Breast Cancer After Endocrine Therapy

April 29th 2024

Trastuzumab deruxtecan improved PFS vs chemotherapy in HR-positive, HER2-low metastatic breast cancer after 1 or more lines of endocrine therapy.

CHMP Recommends Capivasertib/Fulvestrant for Pretreated ER+/HER2– Advanced Breast Cancer With PIK3CA, AKT1, or PTEN Alterations

April 29th 2024

The EMA’s CHMP recommended capivasertib/fulvestrant for ER-positive, HER2-negative advanced breast cancer harboring PIK3CA, AKT1, or PTEN alterations.

Florida Cancer Specialists & Research Institute Clinical Research Driving Progress to Cure Cancer

April 29th 2024

Clinical research conducted at Florida Cancer Specialists & Research Institute, LLC was highlighted at the 2024 AACR Annual Meeting.

FDA Approves Trastuzumab-strf for HER2-Overexpressing Breast and Gastric/GEJ Cancer

April 29th 2024

The FDA has approved trastuzumab-strf for HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or GEJ adenocarcinoma.

Mainstreaming of Genetic Testing Is Tied to Increased Testing Rates in Ovarian Cancer

April 29th 2024

Ying Liu, MD, MPH, and Tiffany Sia, MD, discuss the benefits of mainstreaming genetic testing in patients with ovarian cancer.

MRI-Guided Neoadjuvant Chemotherapy Could be Used in HR-/HER2+ Breast Cancer

April 28th 2024

MRI-guided treatment could be used to optimize the duration of neoadjuvant chemotherapy in hormone receptor-negative/HER2-positive breast cancer.

Understanding Chemotherapy-Related Clonal Hematopoiesis in Ovarian Cancer

April 27th 2024

Sara Corvigno, MD, PhD, expands on an analysis that uncovered the CHIP variants that occurred at a higher frequency in patients with ovarian cancer post-chemotherapy.

Garje Elucidates Biomarker-Driven Approaches Generating Excitement in Metastatic Prostate Cancer

April 26th 2024

Rohan Garje, MD, highlights advances made in precision medicine approaches for the management of metastatic prostate cancer.

Toxicities Hinder Potential Efficacy of Ceritinib/Trametinib in Pretreated Advanced Melanoma

April 26th 2024

Zeynep Eroglu, MD, discusses how findings from a phase 1/2 study of ceritinib and trametinib could help inform future research in melanoma.